Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test may predict infection risk after liver transplant

NCT ID NCT07647978

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with other clinical factors to better identify high-risk patients and potentially improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a tool that helps doctors identify patients at high risk of infection after liver transplant, allowing earlier intervention.
What could go wrong
This is an observational study that does not test a new treatment. The predictive score may not be accurate enough for routine use, and results may not apply to all transplant centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 279 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with severe liver disease waiting for LT. Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients awaiting liver transplantation for one of the following indications: * Compensated cirrhosis complicated by hepatocellular carcinoma * Chronically decompensated cirrhosis (recurrent gastrointestinal bleeding, refractory ascites, portopulmonary or hepatopulmonary syndrome, hepatic encephalopathy, chronic liver failure) * Acute decompensated cirrhosis, with or without associated multiple organ failure (ACLF) * Acute fulminant hepatitis Final inclusion will be : * Patients receiving LT AND * Who provided their consent to participate during the initial enrollment visit AND * For whom the baseline sample (during the day of the LT) was collected Exclusion Criteria: * Minors * Patients under legal guardianship or conservatorship * Pregnant or breastfeeding women * Patients deprived of their liberty * Patients not enrolled in the social security system * Refusal to participate in the study * Patients receiving immunosuppressive therapy prior to LT (with the exception of corticosteroids at a dosage of 40 mg per day for the treatment of alcoholic hepatitis) * Patient who is a candidate for a combined organ transplant * Patient receiving other immunomodulatory therapy (such as immune checkpoint inhibitors) prior to LT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute fulminant hepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver Fibrosis fulminant viral hepatitis hepatitis hepatocellular carcinoma liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute hepatitis Cirrhosis LIVER Mhla-DR

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Hepatology and Gastroenterology - CHU de Clermont Ferrand

    Clermont-Ferrand, 63100, France

  • Department of Hepatology and Gastroenterology - Hôpital Saint Eloi

    Montpellier, 34090, France

  • Department of Hepatology and Gastroenterology - Hôpital de la Croix-Rousse

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.